28-Aug-2026
Cytek Biosciences Faces Mixed Jury Verdict in Patent Case
TipRanks (Mon, 24-Aug 6:29 AM ET)
Jury Finds in Cytek's Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding
Globe Newswire (Fri, 21-Aug 4:35 PM ET)
Cytek Biosciences Reports Second Quarter 2026 Financial Results
Globe Newswire (Wed, 5-Aug 4:05 PM ET)
Cytek Biosciences to Report Second Quarter 2026 Financial Results on August 5, 2026
Globe Newswire (Wed, 22-Jul 4:05 PM ET)
Cytek Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer Engagement
Globe Newswire (Wed, 15-Jul 5:00 PM ET)
Cytek Biosciences to participate at the Singular Research's Las Vegas Invitational Conference
Globe Newswire (Wed, 10-Jun 4:05 PM ET)
Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
PRNewswire (Fri, 5-Jun 7:26 PM ET)
Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026
Globe Newswire (Tue, 2-Jun 5:07 PM ET)
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
Cytek Biosciences trades on the NASDAQ stock market under the symbol CTKB.
As of August 28, 2026, CTKB stock price climbed to $4.68 with 780,738 million shares trading.
CTKB has a beta of 0.09, meaning it tends to be less sensitive to market movements. CTKB has a correlation of 0.00 to the broad based SPY ETF.
CTKB has a market cap of $608.32 million. This is considered a Small Cap stock.
Last quarter Cytek Biosciences reported $48 million in Revenue and -$.09 earnings per share. This fell short of revenue expectation by $-391,760 and missed earnings estimates by -$.07.
In the last 3 years, CTKB traded as high as $9.87 and as low as $2.37.
The top ETF exchange traded funds that CTKB belongs to (by Net Assets): VTI, IWM, VXF, IWN, IBB.
CTKB has underperformed the market in the last year with a return of +12.2%, while SPY returned +19.7%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in CTKB shares. However, CTKB has outperformed the market in the last 3 month and 2 week periods, returning +13.6% and -0.2%, while SPY returned +2.2% and -0.9%, respectively. This indicates CTKB has been having a stronger performance recently.
CTKB support price is $4.45 and resistance is $4.79 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CTKB shares will trade within this expected range on the day.